DNA旋转酶
拓扑异构酶
拓扑异构酶
萘啶酸
喹诺酮类
生物
DNA
酶
生物化学
遗传学
大肠杆菌
细菌
抗生素耐药性
抗生素
基因
作者
Paul G. Higgins,Ad C. Fluit,Franz‐Josef Schmitz
标识
DOI:10.2174/1389450033346920
摘要
The quinolones are a potent group of drugs that target the essential bacterial enzymes DNA gyrase and topoisomerase IV. DNA gyrase is the primary target of Gram negative organisms however, it is topoisomerase IV that is the primary target of Gram positive organisms. Within these enzymes is a highly conserved region centered round the active site where resistance mutations occur. These mutations are almost always identical, irrespective of organism. In spite of the homology of this region, amino acid sequence analysis shows that there are defined differences between the Gram groups, particularly in topoisomerase IV, and it is speculated that herein lies the origin of target preference. Since the first quinolone nalidixic acid was developed, the quinolones have undergone structural modifications, in particular the addition of a fluorine at position 6, to produce the fluoroquinolones. This has seen their potency and pharmakokinetic profile greatly increase. In vitro selection of resistance mutations has allowed the observation of how resistance is acquired and some of the modifications in newer fluoroquinolones have resulted in the shift of primary target from topoisomerase IV to gyrase with Gram positives. Curiously, purified topoisomerase IV is still more sensitive even if gyrase is the primary target. Gyrase remains the primary target for Gram negatives. Keywords: fluoroquinolone, quinolone, gyrase, topoisomerase, mutation, gyra, parc
科研通智能强力驱动
Strongly Powered by AbleSci AI